NUCLEOLIN and cancer: In a study conducted by Khademi et al. (2022), two ligands, HA and the aptamer AS1411, were incorporated on the ChNPs’ surface to target CD44 receptors and nucleolin respectively, to effectively deliver CRISPR/Cas9 to cancer cells.